All News
Febuxostat Safe in Gout with Moderate-Severe Renal Impairment
Renal impairment is a risk factor for gout and a barrier to optimal gout management. Many of the drugs used to treat gout require adjustment in those with renal disease.
Read ArticlePatient's Out-of-Pocket Costs for New Drugs Sky-Rocketing
The good news: in 2015 the FDA approved a record number of new drugs (n=45).
The bad news: most new drugs entering the market today have an exorbitantly high price tag.
Read ArticleRWCS 2016 - Updates in AS, PsA and Lupus
Update on Ankylosing Spondylitis and Spondyloarthritis
Read ArticleSmoking and Age Linked to Development of Inflammatory Arthritis
A prospective cohort of RA first-degree relatives were prospectively studied for genetic and environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies that may influence future development of inflammatory joint symptoms over a 2 year 
Read ArticlePrescribers More Likely to Escalate to Biologics than Triple DMARD Therapy
The paradigm for DMARD use in rheumatoid arthritis (RA) begins with DMARD monotherapy and then escalates to combination therapy with either DMARDs or a combination of conventional DMARD plus a biologic DMARD (bDMARD).
Read ArticleRWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed
Recent Developments in Osteoarthritis, Osteoporosis and Gout
Read ArticleRWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana
The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.
Rheumatoid Arthritis Year in Review
Read ArticleWhat To Do After Teriparatide?
Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?
Read ArticleRheumatoid Modern Management is Better but More Costly
The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.
Read ArticleFDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).
Read ArticleParenteral Methotrexate Intolerance is High in Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.
Read ArticleIncreased Congenital Anomalies in Children from Women with a Juvenile Arthritis History
A Quebec administrative claims analysis examined the birth outcomes of women with a history of juvenile idiopathic arthritis (JIA) who subsequently had a first-time birth (between 1983-2010).
Read ArticleCochrane Review:NSAIDs Equally Effective for Axial Spondyloarthritis
Until the advent of TNF inhibitor therapy, nonsteroidal antiinflammatory drugs (NSAIDs) were the only effective treatment for ankylosing spondylitis or spondyloarthritis (SpA). More recently, several reports have suggested clinical and radiographic benefits to sustained NSAID use.
Read ArticleRheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer
Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.
Read ArticleNo Significant Increased Risk with TNF Inhibitors During Pregnancy
A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)
Read ArticleNIH-Funded Trials Down, While Industry Trials Increase
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Read ArticleUpdated RA Treat-to-Target International Recommendations
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).
Read ArticleBiosimilar Reports - January 2016
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.
Read ArticleRisk of Multiple Sclerosis with TNF Inhibitor Therapy
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Read ArticleUK Audit Shows Early RA Referrals Still Too Slow
A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts.
Read Article